-
-
-
-
-
-
-
Fate Therapeutics reports clinical progress for FT819 lupus treatment
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Neutral Rating on Fate Therapeutics (FATE)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Fate Therapeutics (FATE)
-
-
-
-
-
-
-
Fate Therapeutics (FATE) Tops Q1 EPS by 7c
-
-
-
-
-
-
-
Fate Therapeutics (FATE) announces Scott Wolchko, President and CEO, will retire effective December 31
-
-
-
-
-
-
-
Fate Therapeutics (FATE) Tops Q3 EPS by 2c
-
-
-
-
-
-
-
Fate Therapeutics (FATE) Appoints Neely Mozaffarian to its Board
-
435,222 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

